The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Overt Hepatic Encephalopathy-Global Market Insights and Sales Trends 2024
Synopsis
Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may be gradual or sudden. Other symptoms may include movement problems, changes in mood, or changes in personality. In the advanced stages it can result in a coma.
The global Overt Hepatic Encephalopathy market size is expected to reach US$ 80 million by 2029, growing at a CAGR of 6.4% from 2023 to 2029. The market is mainly driven by the significant applications of Overt Hepatic Encephalopathy in various end use industries. The expanding demands from the Hospitals, Research Institutes, Clinics and Others, are propelling Overt Hepatic Encephalopathy market. Type A (Acute Liver Failure), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Type B (Portal Systemic Bypass Without Liver Disease) segment is estimated at % CAGR for the next seven-year period.
Overt hepatic encephalopathy develops in approximately 40% of patients with cirrhosis during their clinical care. A first episode of overtencephalopathy predicts recurrence in 40% of patients. Aggravating factors for the development of hepatic encephalopathy in advanced liver disease include infection, gastrointestinal bleeding, metabolic disturbance, and receipt of sedative medications. Genetic abnormalities affecting ammonia metabolism can also play a role.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Overt Hepatic Encephalopathy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Overt Hepatic Encephalopathy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Overt Hepatic Encephalopathy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Overt Hepatic Encephalopathy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Overt Hepatic Encephalopathy covered in this report include Alfa Wassermann, Cosmo Pharmaceuticals, Horizon Pharma, KannaLife Sciences, Ocer Therapeutics, Rebiotix, Spherium Biomed, Umecrine Cognition and ASKA Pharmaceutical, etc.
The global Overt Hepatic Encephalopathy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Alfa Wassermann
Cosmo Pharmaceuticals
Horizon Pharma
KannaLife Sciences
Ocer Therapeutics
Rebiotix
Spherium Biomed
Umecrine Cognition
ASKA Pharmaceutical
Mallinckrodt
Valeant
Global Overt Hepatic Encephalopathy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Overt Hepatic Encephalopathy market, Segment by Type:
Type A (Acute Liver Failure)
Type B (Portal Systemic Bypass Without Liver Disease)
Type C (Liver Cirrhosis)
Global Overt Hepatic Encephalopathy market, by Application
Hospitals
Research Institutes
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Overt Hepatic Encephalopathy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Hepatic encephalopathy (HE) is an altered level of consciousness as a result of liver failure. Onset may be gradual or sudden. Other symptoms may include movement problems, changes in mood, or changes in personality. In the advanced stages it can result in a coma.
The global Overt Hepatic Encephalopathy market size is expected to reach US$ 80 million by 2029, growing at a CAGR of 6.4% from 2023 to 2029. The market is mainly driven by the significant applications of Overt Hepatic Encephalopathy in various end use industries. The expanding demands from the Hospitals, Research Institutes, Clinics and Others, are propelling Overt Hepatic Encephalopathy market. Type A (Acute Liver Failure), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Type B (Portal Systemic Bypass Without Liver Disease) segment is estimated at % CAGR for the next seven-year period.
Overt hepatic encephalopathy develops in approximately 40% of patients with cirrhosis during their clinical care. A first episode of overtencephalopathy predicts recurrence in 40% of patients. Aggravating factors for the development of hepatic encephalopathy in advanced liver disease include infection, gastrointestinal bleeding, metabolic disturbance, and receipt of sedative medications. Genetic abnormalities affecting ammonia metabolism can also play a role.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Overt Hepatic Encephalopathy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Overt Hepatic Encephalopathy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Overt Hepatic Encephalopathy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Overt Hepatic Encephalopathy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Overt Hepatic Encephalopathy covered in this report include Alfa Wassermann, Cosmo Pharmaceuticals, Horizon Pharma, KannaLife Sciences, Ocer Therapeutics, Rebiotix, Spherium Biomed, Umecrine Cognition and ASKA Pharmaceutical, etc.
The global Overt Hepatic Encephalopathy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Alfa Wassermann
Cosmo Pharmaceuticals
Horizon Pharma
KannaLife Sciences
Ocer Therapeutics
Rebiotix
Spherium Biomed
Umecrine Cognition
ASKA Pharmaceutical
Mallinckrodt
Valeant
Global Overt Hepatic Encephalopathy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Overt Hepatic Encephalopathy market, Segment by Type:
Type A (Acute Liver Failure)
Type B (Portal Systemic Bypass Without Liver Disease)
Type C (Liver Cirrhosis)
Global Overt Hepatic Encephalopathy market, by Application
Hospitals
Research Institutes
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Overt Hepatic Encephalopathy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Overt Hepatic Encephalopathy
1.1 Overt Hepatic Encephalopathy Market Overview
1.1.1 Overt Hepatic Encephalopathy Product Scope
1.1.2 Overt Hepatic Encephalopathy Market Status and Outlook
1.2 Global Overt Hepatic Encephalopathy Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Overt Hepatic Encephalopathy Market Size by Region (2018-2029)
1.4 Global Overt Hepatic Encephalopathy Historic Market Size by Region (2018-2023)
1.5 Global Overt Hepatic Encephalopathy Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Overt Hepatic Encephalopathy Market Size (2018-2029)
1.6.1 North America Overt Hepatic Encephalopathy Market Size (2018-2029)
1.6.2 Europe Overt Hepatic Encephalopathy Market Size (2018-2029)
1.6.3 Asia-Pacific Overt Hepatic Encephalopathy Market Size (2018-2029)
1.6.4 Latin America Overt Hepatic Encephalopathy Market Size (2018-2029)
1.6.5 Middle East & Africa Overt Hepatic Encephalopathy Market Size (2018-2029)
2 Overt Hepatic Encephalopathy Market by Type
2.1 Introduction
2.1.1 Type A (Acute Liver Failure)
2.1.2 Type B (Portal Systemic Bypass Without Liver Disease)
2.1.3 Type C (Liver Cirrhosis)
2.2 Global Overt Hepatic Encephalopathy Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Overt Hepatic Encephalopathy Historic Market Size by Type (2018-2023)
2.2.2 Global Overt Hepatic Encephalopathy Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Overt Hepatic Encephalopathy Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Overt Hepatic Encephalopathy Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Overt Hepatic Encephalopathy Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Overt Hepatic Encephalopathy Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Overt Hepatic Encephalopathy Revenue Breakdown by Type (2018-2029)
3 Overt Hepatic Encephalopathy Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Research Institutes
3.1.3 Clinics
3.1.4 Others
3.2 Global Overt Hepatic Encephalopathy Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Overt Hepatic Encephalopathy Historic Market Size by Application (2018-2023)
3.2.2 Global Overt Hepatic Encephalopathy Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Overt Hepatic Encephalopathy Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Overt Hepatic Encephalopathy Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Overt Hepatic Encephalopathy Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Overt Hepatic Encephalopathy Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Overt Hepatic Encephalopathy Revenue Breakdown by Application (2018-2029)
4 Overt Hepatic Encephalopathy Competition Analysis by Players
4.1 Global Overt Hepatic Encephalopathy Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Overt Hepatic Encephalopathy as of 2022)
4.3 Date of Key Players Enter into Overt Hepatic Encephalopathy Market
4.4 Global Top Players Overt Hepatic Encephalopathy Headquarters and Area Served
4.5 Key Players Overt Hepatic Encephalopathy Product Solution and Service
4.6 Competitive Status
4.6.1 Overt Hepatic Encephalopathy Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Alfa Wassermann
5.1.1 Alfa Wassermann Profile
5.1.2 Alfa Wassermann Main Business
5.1.3 Alfa Wassermann Overt Hepatic Encephalopathy Products, Services and Solutions
5.1.4 Alfa Wassermann Overt Hepatic Encephalopathy Revenue (US$ Million) & (2018-2023)
5.1.5 Alfa Wassermann Recent Developments
5.2 Cosmo Pharmaceuticals
5.2.1 Cosmo Pharmaceuticals Profile
5.2.2 Cosmo Pharmaceuticals Main Business
5.2.3 Cosmo Pharmaceuticals Overt Hepatic Encephalopathy Products, Services and Solutions
5.2.4 Cosmo Pharmaceuticals Overt Hepatic Encephalopathy Revenue (US$ Million) & (2018-2023)
5.2.5 Cosmo Pharmaceuticals Recent Developments
5.3 Horizon Pharma
5.3.1 Horizon Pharma Profile
5.3.2 Horizon Pharma Main Business
5.3.3 Horizon Pharma Overt Hepatic Encephalopathy Products, Services and Solutions
5.3.4 Horizon Pharma Overt Hepatic Encephalopathy Revenue (US$ Million) & (2018-2023)
5.3.5 KannaLife Sciences Recent Developments
5.4 KannaLife Sciences
5.4.1 KannaLife Sciences Profile
5.4.2 KannaLife Sciences Main Business
5.4.3 KannaLife Sciences Overt Hepatic Encephalopathy Products, Services and Solutions
5.4.4 KannaLife Sciences Overt Hepatic Encephalopathy Revenue (US$ Million) & (2018-2023)
5.4.5 KannaLife Sciences Recent Developments
5.5 Ocer Therapeutics
5.5.1 Ocer Therapeutics Profile
5.5.2 Ocer Therapeutics Main Business
5.5.3 Ocer Therapeutics Overt Hepatic Encephalopathy Products, Services and Solutions
5.5.4 Ocer Therapeutics Overt Hepatic Encephalopathy Revenue (US$ Million) & (2018-2023)
5.5.5 Ocer Therapeutics Recent Developments
5.6 Rebiotix
5.6.1 Rebiotix Profile
5.6.2 Rebiotix Main Business
5.6.3 Rebiotix Overt Hepatic Encephalopathy Products, Services and Solutions
5.6.4 Rebiotix Overt Hepatic Encephalopathy Revenue (US$ Million) & (2018-2023)
5.6.5 Rebiotix Recent Developments
5.7 Spherium Biomed
5.7.1 Spherium Biomed Profile
5.7.2 Spherium Biomed Main Business
5.7.3 Spherium Biomed Overt Hepatic Encephalopathy Products, Services and Solutions
5.7.4 Spherium Biomed Overt Hepatic Encephalopathy Revenue (US$ Million) & (2018-2023)
5.7.5 Spherium Biomed Recent Developments
5.8 Umecrine Cognition
5.8.1 Umecrine Cognition Profile
5.8.2 Umecrine Cognition Main Business
5.8.3 Umecrine Cognition Overt Hepatic Encephalopathy Products, Services and Solutions
5.8.4 Umecrine Cognition Overt Hepatic Encephalopathy Revenue (US$ Million) & (2018-2023)
5.8.5 Umecrine Cognition Recent Developments
5.9 ASKA Pharmaceutical
5.9.1 ASKA Pharmaceutical Profile
5.9.2 ASKA Pharmaceutical Main Business
5.9.3 ASKA Pharmaceutical Overt Hepatic Encephalopathy Products, Services and Solutions
5.9.4 ASKA Pharmaceutical Overt Hepatic Encephalopathy Revenue (US$ Million) & (2018-2023)
5.9.5 ASKA Pharmaceutical Recent Developments
5.10 Mallinckrodt
5.10.1 Mallinckrodt Profile
5.10.2 Mallinckrodt Main Business
5.10.3 Mallinckrodt Overt Hepatic Encephalopathy Products, Services and Solutions
5.10.4 Mallinckrodt Overt Hepatic Encephalopathy Revenue (US$ Million) & (2018-2023)
5.10.5 Mallinckrodt Recent Developments
5.11 Valeant
5.11.1 Valeant Profile
5.11.2 Valeant Main Business
5.11.3 Valeant Overt Hepatic Encephalopathy Products, Services and Solutions
5.11.4 Valeant Overt Hepatic Encephalopathy Revenue (US$ Million) & (2018-2023)
5.11.5 Valeant Recent Developments
6 North America
6.1 North America Overt Hepatic Encephalopathy Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Overt Hepatic Encephalopathy Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Overt Hepatic Encephalopathy Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Overt Hepatic Encephalopathy Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Overt Hepatic Encephalopathy Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Overt Hepatic Encephalopathy Market Dynamics
11.1 Overt Hepatic Encephalopathy Industry Trends
11.2 Overt Hepatic Encephalopathy Market Drivers
11.3 Overt Hepatic Encephalopathy Market Challenges
11.4 Overt Hepatic Encephalopathy Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
